Antitumor mechanisms of targeting the PDK1 pathway in head and neck cancer

Molecular Cancer Therapeutics

Volumn 11, Issue 6, 2012, Pages 1236-1246

  Bhola, Neil E ^a   Freilino, Maria L ^a   Joyce, Sonali C ^a   Sen, Malabika ^a   Thomas, Sufi M ^a   Sahu, Anirban ^a   Cassell, Andre ^a   Chen, Ching Shih ^b   Grandis, Jennifer R ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE; AR 12; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; G PROTEIN COUPLED RECEPTOR; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; FOOD AND DRUG ADMINISTRATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RNA INTERFERENCE; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; HEAD AND NECK NEOPLASMS; HUMANS; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84862544843     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0936     Document Type: Article

References (50)

1. Gschwind A, Prenzel N, Ullrich A. Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation. Cancer Res 2002;62:6329-36. (Pubitemid 35244489)
2. Thomas SM, Bhola NE, Zhang Q, Contrucci SC, Wentzel AL, Freilino ML, et al. Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma. Cancer Res 2006;66:11831-9. (Pubitemid 46094195)
3. Zhang Q, Thomas SM, Xi S, Smithgall TE, Siegfried JM, Kamens J, et al. Src family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res 2004;64:6166-73. (Pubitemid 39129418)
4. Zhang Q, Bhola NE, Lui VWY, Siwak DR, Thomas SM, Gubish CT, et al. Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Mol Cancer Ther 2007;6:1414-24. (Pubitemid 46712005)
5. Zhang Q, Thomas S, Lui V, Xi S, Siegfried J, Fan H, et al. Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin and EGF receptor activation. Proc Natl Acad Sci 2006;103:6901-6.
6. Bhola NE, Thomas SM, Freilino M, Joyce S, Sahu A, Maxwell J, et al. Targeting GPCR-mediated p70S6K activity may improve head and neck cancer response to cetuximab. Clin Cancer Res 2011;17:4996- 5004.
7. Mora A, Komander D, van Aalten DMF, Alessi DR. PDK1, the master regulator of AGC kinase signal transduction. Semin Cell Dev Biol 2004;15:161-70. (Pubitemid 38251644)
8. Sacks PG, Parnes SM, Gallick GE, Mansouri Z, Lichtner R, Satya- Prakash KL, et al. Establishment and characterization of two new squamous cell carcinoma cell lines derived from tumors of the head and neck. Cancer Res 1988;48:2858-66.
9. Biondi RM, Cheung PCF, Casamayor A, Deak M, Currie RA, Alessi DR. Identification of a pocket in the PDK1 kinase domain that interacts with PIF and the C-terminal residues of PKA. EMBO J 2000;19:979-88. (Pubitemid 30119823)
10. Zhu J, Huang JW, Tseng PH, Yang YT, Fowble J, Shiau CW, et al. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide- dependent protein kinase-1 inhibitors. Cancer Res 2004;64:4309-18. (Pubitemid 38802438)
11. Pullen N, Dennis PB, Andjelkovic M, Dufner A, Kozma SC, Hemmings BA, et al. Phosphorylation and activation of p70s6k by PDK1. Science 1998;279:707-10.
12. Yacoub A, Park MA, Hanna D, Hong Y, Mitchell C, Pandya AP, et al. OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells. Mol Pharmacol 2006;70:589-603. (Pubitemid 44092320)
13. Haiming D, Chunhua H, Dongmei G, Dasheng W, Ching-Shih C, Steven MDA. OSU03012 activates Erk1/2 and Cdks leading to the accumulation of cells in the S-phase and apoptosis. Int J Cancer 2008;123:2923-30.
14. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PRJ, Reese CB, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B[alpha]. Curr Biol 1997;7:261-9. (Pubitemid 27176852)
15. Nakamura K, Sakaue H, Nishizawa A, Matsuki Y, Gomi H, Watanabe E, et al. PDK1 regulates cell proliferation and cell cycle progression through control of cyclin D1 and p27Kip1 expression. J Biol Chem 2008;283:17702-11.
16. Kalish LH, Kwong RA, Cole IE, Gallagher RM, Sutherland RL, Musgrove EA. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines. Clin Cancer Res 2004;10:7764-74. (Pubitemid 39557542)
17. Burkhard ML, Shirley KK, Verena F, Wolf M, Roland HS. Dynamic survivin in head and neck cancer: Molecular mechanism and therapeutic potential. Int J Cancer 2007;121:1169-74.
18. Marioni G, D'Alessandro E, Bertolin A, Staffieri A. Survivin multifaceted activity in head and neck carcinoma: Current evidence and future therapeutic challenges. Acta Otolaryngol 2010;130:4-9.
19. Abrahao AC, Castilho RM, Squarize CH, Molinolo AA, Santos-Pinto Dd Jr, Gutkind JS. A role for COX2-derived PGE2 and PGE2-receptor subtypes in head and neck squamous carcinoma cell proliferation. Oral Oncol 2010;46:880-7.
20. Zhang W, Bhola N, Kalyankrishna S, Gooding W, Hunt J, Seethala R, et al. Kinin B2 receptor mediates induction of cyclooxygenase-2 and is overexpressed in head and neck squamous cell carcinomas. Mol Cancer Res 2008;6:1946-56.
21. Amorino G, Deeble P, Parsons S. Neurotensin stimulates mitogenesis of prostate cancer cells through a novel c-Src/Stat5b pathway. Oncogene 2007;26:745-56. (Pubitemid 46204253)
22. Barki-Harrington L, Daaka Y. Bradykinin induced mitogenesis of androgen independent prostate cancer cells. J Urol 2001;165:2121-5.
23. Bergmann S, Junker K, Henklein P, Hollenberg M, Settmacher U, Kaufmann R. PAR-type thrombin receptors in renal carcinoma cells: PAR1-mediated EGFR activation promotes cell migration. Oncol Rep 2006;15:889-93.
24. Daub H, Ulrich Weiss F, Wallasch C, Ullrich A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 1996;379:557-60. (Pubitemid 26049585)
25. Ding Y, Shi RH, Tong JD, Li X, Zhang GX, Xiao WM, et al. PGE2 upregulates vascular endothelial growth factor expression in MKN28 gastric cancer cells via epidermal growth factor receptor signaling system. Exp Oncol 2005;27:108-13. (Pubitemid 41025731)
26. Fishman DA, Liu Y, Ellerbroek SM, Stack MS. Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res 2001;61:3194-9. (Pubitemid 32691975)
27. Luppi F, Longo AM, de Boer WI, Rabe KF, Hiemstra PS. Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation. Lung Cancer 2006;56:25-33.
28. McCole DF, Keely SJ, Coffey RJ, Barrett KE. Transactivation of the epidermal growth factor receptor in colonic epithelial cells by carbachol requires extracellular release of transforming growth factor-alpha. J Biol Chem 2002;277:42603-12. (Pubitemid 35285629)
29. Gschwind A, Hart S, Fischer OM, Ullrich A. TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. EMBO J 2003;22:2411-21. (Pubitemid 36604980)
30. Luttrell LM, Hawes BE, van Biesen T, Luttrell DK, Lansing TJ, Lefkowitz RJ. Role of c-Src tyrosine kinase in G protein-coupled receptor and Gbeta gamma subunit-mediated activation of mitogen-activated protein kinases. J Biol Chem 1996;271:19443-50. (Pubitemid 26271617)
31. Pages-Borrell M, Rojo F, Albanell J, Baselga J, Arribas J. TACE is required for activation of EGFR by TGF-alpha in tumors. EMBO J 2003;22:1114-24. (Pubitemid 36313595)
32. Kenny PA. Targeting TACE-dependent EGFR ligand shedding in breast cancer. J Clin Invest 2007;117:337-45. (Pubitemid 46203962)
33. Wang SE, Xiang B, Guix M, Olivares MG, Parker J, Chung CH, et al. Transforming growth factor {beta} engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol Cell Biol 2008;28:5605-20.
34. She QB, Solit DB, Ye Q, O'Reilly KE, Lobo J, Rosen N. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 2005;8:287-97. (Pubitemid 41443414)
35. Ellwood-Yen K, Keilhack H, Kunii K, Dolinski B, Connor Y, Hu K, et al. PDK1 attenuation fails to prevent tumor formation in PTEN-deficient transgenic mouse models. Cancer Res 2011;71:3052-65.
36. Krysan K, Reckamp KL, Dalwadi H, Sharma S, Rozengurt E, Dohadwala M, et al. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res 2005;65:6275-81. (Pubitemid 40994413)
37. Adomeitt A, Graness A, Gros S, Seedorf K, Wetzker R, Liebmann C. Bradykinin B2 receptor-mediated mitogen-activated protein kinase activation in COS-7 cells requires dual signaling vis both protein kinase C pathway and epidermal growth factor receptor transactivation. Mol Cell Biol 1999;19:5289-97. (Pubitemid 29339888)
38. Graness A, Hanke S, Boehmer FD, Presek P, Liebmann C. Protein-tyrosine- phosphatase-mediated epidermal growth factor(EGF) receptor transactivation and EGF receptor-independent stimulation of mitogen- activated protein kinase by bradykinin in A431 cells. Biochem J 2000;347:441-7. (Pubitemid 30229391)
39. Xia S, Chen Z, Forman LW, Faller DV. PKC[delta] survival signaling in cells containing an activated p21Ras protein requires PDK1. Cell Signal 2009;21:502-8.
40. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000;275:11397-403. (Pubitemid 30212792)
41. Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P, et al. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 2002;277:27613-21. (Pubitemid 34966703)
42. Park MA, Yacoub A, Rahmani M, Zhang G, Hart L, Hagan MP, et al. OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells. Mol Pharmacol 2008;73:1168-84. (Pubitemid 351439199)
43. Ryan E, Bushnell T, Friedman A, Rahman I, Phipps R. Cyclooxygenase- 2 independent effects of cyclooxygenase-2 inhibitors on oxidative stress and intracellular glutathione content in normal and malignant human B-cells. Cancer Immunol Immunother 2008;57:347-58. (Pubitemid 350301954)
44. Wang YC, Kulp SK, Wang D, Yang CC, Sargeant AM, Hung JH, et al. Targeting endoplasmic reticulum stress and Akt with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor receptor inhibitors. Cancer Res 2008;68:2820-30. (Pubitemid 351556281)
45. Porchia LM, Guerra M, Wang YC, Zhang Y, Espinosa AV, Shinohara M, et al. 2-Amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol- 1-yl]-phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase. Mol Pharmacol 2007;72: 1124-31. (Pubitemid 350012586)
46. Murphy ST, Bailey S, Burke BJ, Chappie TA, Ferre R, Greasley S, et al. Discovery of novel, potent and selective inhibitors of 3- phosphoinositide- dependent kinase (PDK1). J Med Chem 2011;54: 8490-500.
47. Gadgeel S, Ruckdeschel J, Heath E, Heilbrun L, Venkatramanamoorthy R, Wozniak A. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC). J Thoracic Oncol 2007;2: 299-305. (Pubitemid 47181712)
48. Reckamp KL, Krysan K, Morrow JD, Milne GL, Newman RA, Tucker C, et al. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin Cancer Res 2006;12:3381-8.
49. Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824-32. (Pubitemid 28280548)
50. Jameson MJ, Beckler AD, Taniguchi LE, Allak A, VanWagner LB, Lee NG, et al. Activation of epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells. Mol Cancer Ther 2011;10:2124-34.